Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?

In the MCL patients treated on the BRUIN trial, treatment was well tolerated in general with a low rate of treatment discontinuation or dose reduction. As far as cardiac toxicities, no grade ≥3 treatment emergent AEs of hypertension were observed. Atrial fibrillation/flutter (AF) was reported in 6 (...

As part of a safety analysis, we presented an abstract at ASH 2022 to specifically look at pirtobrutinib in a subset of patients who stopped a prior covalent inhibitor due to a toxicity/intolerance issue. Interestingly, this analysis demonstrated that the majority of patients (nearly 80%) who stoppe...